Switzerland· 65148002
Signifor LAR 40 mg, Pulver und Lösung zur Herstellung einer Injektionssuspension
A pasireotide product containing pasireotidum, registered in Switzerland by RECORDATI AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Pasireotide is registered in 15 of 19 countries.
Countries holding a registration under ATC H01CB05 (pasireotide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Pasireotide · ATC H01CB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pasireotide costs, country by country.
Normalised to the WHO defined daily dose (1.2 mg), so markets compare like for like.
- Switzerland: $238.10 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Pasireotide · price per daily dose (1.2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$238.10
The record
At a glance
Swissmedic (Switzerland)- Active substance
- pasireotidum
- Manufacturer
- RECORDATI AG
- Country
- Switzerland (CH)
- ATC code
- H01CB05
- ATC class
- Pasireotide
- Defined daily dose
- 1.2 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680651480029Durchstf 1 StkCHF 3291.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
435 interactions on record for pasireotide.
Graded by severity as the source publishes them — 246 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pasireotide · interactions on record
435 records
- 246 severe
- 184 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pasireotide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainSIGNIFOR 0,3 MG SOLUCION INYECTABLERecordati Rare Diseases
- IcelandSigniforRecordati Rare Diseases*
- PolandSigniforRecordati Rare Diseases
- SwedenSignifor 0,3 mg Injektionsvätska, lösningRecordati Rare Diseases
- CanadaSIGNIFORRECORDATI RARE DISEASES CANADA INC
- NetherlandsSignifor 0,3 mg oplossing voor injectieRecordati Rare Diseases
- IrelandSignifor 0.3 mg solution for injectionRecordati Rare Diseases
- United KingdomSignifor 0.3mg/1ml solution for injection ampoulesRecordati Rare Diseases UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Signifor
- Liechtenstein · Signifor
- Norway · Signifor
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf5afe96-0f47-49a3-b250-979b9858ba29 GET /v1/drugs/bf5afe96-0f47-49a3-b250-979b9858ba29?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "pasireotidum 40 mg",
"valid_from": "2015-06-01",
"limitations": "[{\"description\":\"Signifor LAR ist indiziert zur Behandlung der Akromegalie bei Patienten, bei denen eine Operation und/oder eine Strahlentherapie und andere medizinische Therapien (Somatostatin-Analoga) nicht den gewünschten Behandlungserfolg erzielten bzw. bei denen keine dieser Therapien adäquat ist (second line).\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2015-06-01\"}]",
"galenic_form": "Trockensub 40 mg cum solv",
"therapeutic_area": null,
"sl_inclusion_date": "2015-06-01",
"self_retention_pct": 10
}See everything about pasireotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.